Pittsburgh, USA – June 21, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, is proud to showcase its presence at the St. Louis Wound & Vascular Symposium, being held today, Saturday, June 21, 2025, in St. Louis, MO. Attendees are invited to experience firsthand the transformative capabilities of the MolecuLight DX™ multimodal imaging platform, now featuring recently released thermal imaging alongside its renowned fluorescence technology, at Booth #4.
The St. Louis Wound & Vascular Symposium is a one-day event that unites healthcare professionals and industry experts to explore the latest advancements in wound and vascular treatment. MolecuLight is eager to demonstrate how its advanced imaging technology provides clinicians with objective, real-time, and comprehensive information on bacterial presence, wound measurement, and skin temperature changes, empowering more precise, targeted, and effective treatment decisions.
“We are incredibly excited to engage with the wound care community at the St. Louis Wound & Vascular Symposium,” says Anil Amlani, CEO of MolecuLight. “As a conference dedicated to highlighting new treatment advancements, we are proud that MolecuLight’s innovative multimodal platform exemplifies these strides in wound care. Our devices are truly transforming how clinicians assess wounds by providing vital visual data, directly at the point of care. This comprehensive view is essential for optimizing patient outcomes and standardizing best practices. We look forward to demonstrating these powerful capabilities and discussing their clinical impact with attendees at Booth #4.”
The MolecuLight DX™ platform stands as an indispensable tool, offering unparalleled, actionable insights that empower wound care specialists globally. Its real-time fluorescence visualization of bacteria, combined with digital wound measurement and new thermal capabilities, provides a comprehensive view for optimizing wound treatments – from guiding targeted debridement and sampling for microbiology, to assessing thermal patterns for inflammation or perfusion issues, and objectively monitoring wound and treatment progress, ultimately leading to more effective patient care.
About MolecuLight Corp and its wound imaging devices
MolecuLight Corp., is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.
For sales, media or other inquiries or further information, please contact:
Danielle Dunham
Director of Marketing and Product Management
MolecuLight Inc.
ddunham@moleculight.com
T. +1.416.542.5524
us.moleculight.com
